Intraperitoneal chemotherapy for ovarian cancer with peritoneal metastases, systematic review of the literature and focused personal experience.
Ovarian
cancer
chemotherapy
cisplatin
consolidation surgery
intraperitoneal chemotherapy
paclitaxel
salvage surgery
surgery for recurrence
upfront surgery
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
ppublish
Résumé
Epithelial ovarian cancer (EOC) causes 60% of ovarian cancer cases and is the fourth most common cause of death from cancer in women. The standard of care for EOC includes a combination of surgery followed by intravenous chemotherapy. Intraperitoneal (IP) chemotherapy (CT) has been introduced into the therapeutic algorithm of EOC with positive results. To explore existing results regarding intraperitoneal chemotherapy a systematic review of the literature and an analysis of our own institutional prospective database of patients treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) for EOC at different stages were conducted. The focused report concerning our personal experience with advanced EOC treated with cytoreductive surgery and HIPEC produced the following results: In 57 patients cisplatin + paclitaxel as HIPEC was the only significant factor improving overall survival (OS) at multivariate analysis (OR 6.54, 95% CI: 1.24-34.47, P=0.027). Patients treated with HIPEC cisplatin + paclitaxel showed a median OS of 46 months (SD 6.4, 95% CI: 33.4-58.6), while patients treated with other HIPEC regimens showed a median OS of 12 months (SD 3.1, 95% CI: 6.0-18.0). The 2y-OS was 72% and 3y-OS was 68% for cisplatin + paclitaxel as HIPEC, while the 2y- and 3y-OS was 0% for other HIPEC regimens. Patients treated with HIPEC cisplatin + paclitaxel showed a median disease-free survival (DFS) of 13 months (SD 1.6, 95% CI: 9.9-16.1), while patients treated with other HIPEC regimens showed a median DFS of 8 months (SD 3.1, 95% CI: 1.9-14.1). In conclusion, HIPEC cisplatin + paclitaxel in ovarian cancer showed positive results that may be considered semi-definitive according to the level of evidence and should be considered a starting point for further investigations. At present HIPEC cisplatin + paclitaxel should be proposed to patients with advanced ovarian cancer as standard treatment at almost all stages of disease. Platinum + taxane-based intraperitoneal regimens demonstrated superior results compared to other regimens.
Identifiants
pubmed: 33968435
doi: 10.21037/jgo-2020-06
pii: jgo-12-S1-S144
pmc: PMC8100719
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
S144-S181Commentaires et corrections
Type : CommentIn
Informations de copyright
2021 Journal of Gastrointestinal Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo-2020-06). The focused issue was sponsored by the Peritoneal Surface Oncology Group International (PSOGI). The authors have no other conflicts of interest to declare.
Références
Eur J Surg Oncol. 2009 Nov;35(11):1186-91
pubmed: 19356887
Gynecol Oncol. 2018 Jul;150(1):23-30
pubmed: 29743140
Int J Hyperthermia. 2015 Feb;31(1):8-14
pubmed: 25559985
Zentralbl Gynakol. 2003 Oct;125(10):424-9
pubmed: 14628225
J Surg Oncol. 2010 Nov 1;102(6):663-70
pubmed: 20721959
J BUON. 2015 May;20 Suppl 1:S12-28
pubmed: 26051328
Tumori. 2001 May-Jun;87(3):120-6
pubmed: 11504363
Int J Hyperthermia. 1999 Mar-Apr;15(2):79-107
pubmed: 10323618
Diagnostics (Basel). 2020 Jan 14;10(1):
pubmed: 31947647
Eur J Surg Oncol. 2013 Dec;39(12):1435-43
pubmed: 24209430
Ann Surg Oncol. 2015 May;22(5):1570-5
pubmed: 25391263
J Egypt Natl Canc Inst. 2018 Dec;30(4):139-141
pubmed: 30470604
Int J Gynecol Cancer. 2017 Feb;27(2):246-247
pubmed: 28114231
Eur J Surg Oncol. 2019 Mar;45(3):301-309
pubmed: 30786961
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Clin Transl Oncol. 2009 Nov;11(11):753-9
pubmed: 19917539
Cancer. 2019 Dec 15;125 Suppl 24:4594-4597
pubmed: 31967685
Int J Hyperthermia. 2018 Aug;34(5):564-569
pubmed: 28877609
Gynecol Oncol. 2011 Aug;122(2):221-5
pubmed: 21543112
Nat Prod Rep. 2014 Mar;31(3):335-55
pubmed: 24481420
Int J Hyperthermia. 2018 Aug;34(5):570-577
pubmed: 29298538
Int J Gynecol Cancer. 2012 Jun;22(5):778-85
pubmed: 22572845
N Engl J Med. 2018 Apr 5;378(14):1363-1364
pubmed: 29617590
Ann Surg Oncol. 2016 May;23(5):1660-5
pubmed: 26714958
J Oncol. 2012;2012:358341
pubmed: 22481924
J Gynecol Oncol. 2015 Jan;26(1):54-61
pubmed: 25376916
Int J Biomed Sci. 2016 Dec;12(4):120-124
pubmed: 28190981
J Gynecol Oncol. 2019 Jul;30(4):e59
pubmed: 31074245
Acta Obstet Gynecol Scand. 2015 Apr;94(4):435-9
pubmed: 25675854
Gynecol Obstet Fertil. 2004 May;32(5):391-7
pubmed: 15177208
J Clin Oncol. 2004 Aug 15;22(16):3284-92
pubmed: 15310771
Ren Fail. 2014 Nov;36(10):1486-91
pubmed: 25155314
Br J Cancer. 2015 Jan 20;112(2):306-12
pubmed: 25461804
J Turk Ger Gynecol Assoc. 2019 Jul 31;20(4):213-217
pubmed: 31362486
Eur J Surg Oncol. 2010 Jun;36(6):589-93
pubmed: 20466507
Gynecol Oncol. 1990 Jan;36(1):1-6
pubmed: 2403957
Perit Dial Int. 2008 Jan-Feb;28(1):61-6
pubmed: 18178949
Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203
pubmed: 14656280
Eur J Obstet Gynecol Reprod Biol. 2020 Jan;244:101-105
pubmed: 31778904
J Surg Oncol. 2013 May;107(6):591-6
pubmed: 23129533
J BUON. 2012 Oct-Dec;17(4):735-9
pubmed: 23335534
Int J Gynecol Cancer. 2010 Jan;20(1):61-9
pubmed: 20130504
Eur J Gynaecol Oncol. 2016;37(5):638-643
pubmed: 29787001
Cancer Res. 1987 Aug 1;47(15):4038-42
pubmed: 3607749
Cancer Res. 1979 Aug;39(8):3209-14
pubmed: 455305
World J Surg. 2004 Oct;28(10):1040-5
pubmed: 15573262
Clin Transl Oncol. 2019 Oct;21(10):1357-1363
pubmed: 30788835
Gynecol Oncol. 2015 May;137(2):223-8
pubmed: 25701703
Anticancer Res. 2015 Sep;35(9):4997-5005
pubmed: 26254399
Int J Gynecol Cancer. 2016 Jun;26(5):912-7
pubmed: 27051055
Surg Oncol Clin N Am. 2003 Jul;12(3):825-33
pubmed: 14567034
J Gynecol Oncol. 2018 May;29(3):e53
pubmed: 29533028
Br J Cancer. 2019 Aug;121(5):425-428
pubmed: 31383985
Patient Saf Surg. 2012 Jun 15;6(1):12
pubmed: 22709648
J Surg Oncol. 2006 Sep 15;94(4):316-24
pubmed: 16917864
Int J Hyperthermia. 2017 Aug;33(5):548-553
pubmed: 28092994
J Surg Oncol. 2014 Nov;110(6):661-5
pubmed: 24962381
World J Surg Oncol. 2004 Jun 28;2:21
pubmed: 15222884
Eur J Gynaecol Oncol. 2016;37(2):194-8
pubmed: 27172744
World J Surg. 2007 Sep;31(9):1813-1820
pubmed: 17629740
Drug Metab Dispos. 2012 Dec;40(12):2365-73
pubmed: 22972909
Gynecol Oncol. 2017 May;145(2):236-242
pubmed: 28341300
Langenbecks Arch Surg. 2011 Oct;396(7):1077-81
pubmed: 21842290
Cancer Treat Rep. 1979 Feb;63(2):269-73
pubmed: 445504
J Chemother. 2004 Nov;16 Suppl 5:23-5
pubmed: 15675471
Ann Surg Oncol. 2016 Apr;23(4):1294-301
pubmed: 26628430
Eur J Surg Oncol. 2006 Aug;32(6):671-5
pubmed: 16621425
J Oncol. 2010;2010:497429
pubmed: 20066162
Int J Gynecol Cancer. 2005 Mar-Apr;15(2):233-9
pubmed: 15823105
Oncologist. 2005 Feb;10(2):112-22
pubmed: 15709213
Cancer Chemother Pharmacol. 2009 Apr;63(5):799-805
pubmed: 18654746
Bull Cancer. 2010 Apr;97(4):E23-32
pubmed: 20202920
Gynecol Obstet Fertil. 2013 Sep;41(9):493-8
pubmed: 23972918
Gynecol Oncol. 2009 Jun;113(3):335-40
pubmed: 19345401
Int J Hyperthermia. 2016 May;32(3):281-8
pubmed: 26862667
Gynecol Oncol. 2014 Feb;132(2):307-11
pubmed: 24275155
Minerva Chir. 2014 Feb;69(1):27-35
pubmed: 24675244
Eur J Surg Oncol. 2013 Oct;39(10):1109-15
pubmed: 23870278
Surg Oncol. 2016 Sep;25(3):164-70
pubmed: 27566018
Asian Pac J Cancer Prev. 2019 Feb 26;20(2):621-627
pubmed: 30806069
Clin Exp Metastasis. 2021 Apr;38(2):255
pubmed: 31811526
Eur J Surg Oncol. 2014 Aug;40(8):970-5
pubmed: 24035502
Nat Rev Clin Oncol. 2013 Apr;10(4):211-24
pubmed: 23381004
Cancer Treat Rev. 1986 Dec;13(4):219-42
pubmed: 3545463
J Ovarian Res. 2019 Apr 17;12(1):33
pubmed: 30995948
Oncol Rep. 2005 Jan;13(1):121-5
pubmed: 15583812
Eur J Cancer. 2006 Sep;42(14):2296-302
pubmed: 16901687
Transl Oncol. 2016 Apr;9(2):130-138
pubmed: 27084429
Gynecol Oncol. 2014 Sep;134(3):468-72
pubmed: 25042672
Ann Surg Oncol. 2015 Mar;22(3):987-93
pubmed: 25212832
Pharmacol Ther. 1991;49(3):293-309
pubmed: 2052627
Int J Hyperthermia. 2017 Aug;33(5):554-561
pubmed: 28540830
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
Cancer Res. 1989 Jun 15;49(12):3380-4
pubmed: 2720692
World J Surg. 2003 Jun;27(6):640-6
pubmed: 12734680
Minerva Ginecol. 2017 Apr;69(2):119-127
pubmed: 27415829
Bull Cancer. 2009 Dec;96(12):1235-42
pubmed: 19923051
Int J Hyperthermia. 2018;35(1):370-374
pubmed: 30300042
J Surg Oncol. 2019 Dec;120(7):1208-1219
pubmed: 31531879
Int J Cancer. 2015 Feb 1;136(3):699-708
pubmed: 24895230
Gynecol Oncol. 2015 Jan;136(1):130-5
pubmed: 25434634
Cancer Res. 1982 Oct;42(10):4265-9
pubmed: 7105021
Ann Oncol. 2012 Mar;23(3):647-652
pubmed: 21685413
Eur J Surg Oncol. 2021 Jan;47(1):101-107
pubmed: 31128948
Langenbecks Arch Surg. 2014 Jun;399(5):589-94
pubmed: 24817542
Oncology. 1998 Mar-Apr;55(2):130-8
pubmed: 9499187
Gynecol Oncol. 2007 Apr;105(1):90-6
pubmed: 17173957
Clin Exp Metastasis. 2019 Oct;36(5):433-439
pubmed: 31270731
Eur J Surg Oncol. 2000 Nov;26(7):663-8
pubmed: 11078613
Gynecol Oncol. 2013 Apr;129(1):81-5
pubmed: 23352917
J Visc Surg. 2014 Oct;151(5):347-53
pubmed: 25168575
Ann Surg Oncol. 2018 Nov;25(12):3701-3708
pubmed: 30128899
Surg Oncol Clin N Am. 2012 Oct;21(4):577-97
pubmed: 23021717
Gynecol Oncol. 2014 Feb;132(2):303-6
pubmed: 24378877
Semin Oncol. 1995 Jun;22(3 Suppl 6):84-7
pubmed: 7597437
Eur J Surg Oncol. 2016 Jun;42(6):909-10
pubmed: 26965304
Updates Surg. 2019 Jun;71(2):389-394
pubmed: 30406932
Ann Surg Oncol. 2015 Feb;22(2):655-61
pubmed: 25155402
J Surg Oncol. 2019 Sep;120(3):550-557
pubmed: 31267569
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi
pubmed: 14567020
Int J Hyperthermia. 2016 Aug;32(5):488-95
pubmed: 27056558
Ann Surg. 2011 Jul;254(1):138-44
pubmed: 21494122
Ann Surg Oncol. 2014 Oct;21(11):3621-7
pubmed: 24819120
J Surg Oncol. 2010 Feb 1;101(2):149-55
pubmed: 20035540
Gynecol Oncol. 2012 Dec;127(3):502-5
pubmed: 23022234
BJOG. 2012 Jun;119(7):800-9
pubmed: 22571746
Cancer Chemother Pharmacol. 2017 Aug;80(2):405-410
pubmed: 28669065
Chemotherapy. 2016;61(5):240-8
pubmed: 26930357
J Clin Oncol. 2002 Feb 1;20(3):694-8
pubmed: 11821450
Cancer. 2008 Jul 15;113(2):315-25
pubmed: 18473354
Ann Surg Oncol. 2012 Dec;19(13):4052-8
pubmed: 22825772
Minerva Chir. 2014 Feb;69(1):17-26
pubmed: 24675243
Pharmazie. 2014 Feb;69(2):125-7
pubmed: 24640601
J Surg Oncol. 2011 Jan 1;103(1):10-6
pubmed: 21031424
Gynecol Oncol. 2003 Nov;91(2):341-5
pubmed: 14599864
Proc Natl Acad Sci U S A. 1979 Feb;76(2):954-7
pubmed: 34156